CytomX Therapeutics, Inc.
$4.89
0%
2026-04-21 06:16:01
www.cytomx.com
NMS: CTMX
Explore CytomX Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.06 B
Current Price
$4.89
52W High / Low
$8.21 / $0.61
Stock P/E
—
Book Value
$0.58
Dividend Yield
—
ROCE
-21.31%
ROE
-35.25%
Face Value
—
EPS
$-0.15
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
69
Beta
2.48
Debt / Equity
4.28
Current Ratio
3.09
Quick Ratio
3.09
Forward P/E
-9.28
Price / Sales
12.45
Enterprise Value
$614.31 M
EV / EBITDA
-33.77
EV / Revenue
8.06
Rating
Strong Buy
Target Price
$13.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | IDEAYA Biosciences, Inc. | $33.6 | — | $2.95 B | — | -15.17% | -10.92% | $39.28 / $16.07 | $11.65 |
| 2. | Savara Inc. | $5.61 | — | $1.15 B | — | -52.68% | -63.45% | $7 / $1.89 | $0.8 |
| 3. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 4. | Dermata Therapeutics, Inc. | $1.34 | — | $5.47 M | — | -124.91% | -1.94% | $9.9 / $1.1 | $2.34 |
| 5. | ALX Oncology Holdings Inc. | $1.75 | — | $219.79 M | — | -292.37% | -1.46% | $2.66 / $0.4 | $0.48 |
| 6. | Solid Biosciences Inc. | $8.49 | — | $835.34 M | — | -90.02% | -1.1% | $8.87 / $2.41 | $2.28 |
| 7. | DiaMedica Therapeutics Inc. | $6.56 | — | $369.1 M | — | -61.16% | -67.68% | $10.42 / $3.28 | $1.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.66 M | 5.96 M | 18.66 M | 50.92 M | 38.09 M | — |
| Operating Profit | -27.93 M | -15.77 M | -1.29 M | 22.62 M | 17.68 M | — |
| Net Profit | -26.51 M | -14.23 M | -0.15 M | 23.52 M | 18.88 M | — |
| EPS in Rs | -0.12 | -0.07 | -0 | 0.11 | 0.09 | 0.07 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 76.2 M | 138.1 M | 101.21 M | 53.16 M |
| Operating Profit | -22.36 M | 25 M | -6.48 M | -101.33 M |
| Net Profit | -17.37 M | 31.87 M | -0.57 M | -99.32 M |
| EPS in Rs | -0.08 | 0.15 | -0 | -0.46 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 151.57 M | 120.53 M | 201.79 M | 260.89 M |
| Total Liabilities | 52.56 M | 120.99 M | 249.24 M | 346.64 M |
| Equity | 99.01 M | -0.46 M | -47.45 M | -85.75 M |
| Current Assets | 143.92 M | 107.31 M | 182.94 M | 237.1 M |
| Current Liabilities | 46.62 M | 85.77 M | 155.91 M | 152.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -75.59 M | -86.23 M | -56.03 M | -110.79 M |
| Investing CF | -59.74 M | 99.7 M | -150.67 M | 98.26 M |
| Financing CF | 110.45 M | 7.52 M | 30.23 M | 0.65 M |
| Free CF | -75.81 M | -86.54 M | -56.88 M | -112.53 M |
| Capex | -0.22 M | -0.31 M | -0.84 M | -1.74 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 36.45% | 90.38% | — | — |
| Earnings Growth % | 5700.88% | 99.43% | — | — |
| Profit Margin % | 23.08% | -0.56% | -186.82% | — |
| Operating Margin % | 18.1% | -6.41% | -190.61% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | 19.38% | -4.26% | -186.02% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.